-
.
- Ελληνικά
The Ministry of Health informs the public that from Thursday 21/12/2023, the COVID-19 vaccine, Nuvaxovid HBV.1.5 from Novavax, will be available for people over 18 years of age.
Nuvaxovid may be administered for a baseline vaccination cycle or as a booster dose to persons 18 years of age and older, following a baseline cycle consisting of an mRNA or adenovirus vector vaccine.
Beneficiaries wishing to be vaccinated with the Nuvaxovid vaccine will be able to be served through vaccination centres operating in all provinces, only by arranging telephone appointments.
Note that arrangements for COVID - 19 vaccinations with Pfizer's vaccine, as well as for influenza vaccinations, remain the same (walk in).
It is recalled that for the administration of the vaccines:
- an identification document (ID card, passport, Alien Registration Number)
- for persons previously vaccinated with COVID-19 vaccine, the vaccination can be given at 5 months after the last vaccination given
- a minimum of 3 months must be observed for vaccination against COVID-19 after a positive test against COVID-19
In case a beneficiary wishes to be vaccinated only with the COVID-19 vaccine or on the same day with both vaccines (COVID-19 and seasonal influenza)
- a minimum of 3 months must be observed for vaccination against COVID-19 after a positive test against COVID-19
In case a beneficiary wishes to be vaccinated only with the COVID-19 vaccine or on the same day with both vaccines (COVID-19 and seasonal influenza), then they can be served at the vaccination centres of the Ministry of Health. Vaccination of those who are not beneficiaries of the GHS, but who belong to the high-risk groups, will be provided free of charge at Adult Vaccination Centres of the Ministry of Health.
The vaccination of beneficiaries of the General Health Insurance Scheme with the seasonal influenza vaccine, who belong to the high-risk groups, may be carried out by the Personal Physician by appointment.
(DK)
Contents of this article including associated images are owned by PIO
Views & opinions expressed are those of the author and/or PIO
Source
